• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

App Note: Building a High-throughput and Automated Liver-on-a-chip Model for Hepatotoxicity Detection

Drug induced liver injury (DILI) is the leading cause of approved drug withdrawal from the market and presents a major health concern as more than 50% of acute liver failures are caused by DILI. Identification of hepatotoxic compounds in the preclinical phase of drug development is key to preventing DILI, however currently employed animal and two-dimensional (2D) in vitro models often fail to predict clinical hepatotoxicity.

Physiologically relevant and efficient in vitro models that mimic the human liver microenvironment and clinical outcome are necessary. Microphysiological system (MPS) models of the liver, or liver-on-a-chip models, incorporate principal characteristics of the in vivo liver such as 3D structure, co-culture, and perfusion. However, many MPS liver models require complex assembly and therefore are low- throughput, limiting their use in a drug screening capacity.

In this application note, we demonstrate the development and assessment of a 3D microfluidic liver-on-a-chip model in the OrganoPlate®, ready to be used for high-throughput hepatotoxicity screening: the OrganoPlate LiverToxTM.


Benefits of the model:

  • A robust and validated liver-on-a-chip model to use for high-throughput hepatotoxicity screening
  • Recapitulate the in vivo liver through a 3D three liver-cell type model, without the use of animals
  • Perform a compound library screen to assess, rank, and prioritize compounds for follow-up mechanistic studies

 

Download the app note here

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all